MCID: SCH014
MIFTS: 62

Schistosomiasis

Categories: Rare diseases, Infectious diseases, Blood diseases

Aliases & Classifications for Schistosomiasis

Summaries for Schistosomiasis

NIH Rare Diseases : 49 Schistosomiasis is a disease caused by parasitic worms. Although the worms that cause schistosomiasis are not found in the United States, more than 200 million people are infected worldwide. Infection occurs through contact with contaminated water. The parasite in its infective stages is called a cercaria. It swims freely in open bodies of water. On contact with humans, the parasite burrows into the skin, matures into another stage (schistosomula), then migrates to the lungs and liver, where it matures into the adult form. The adult worm then migrates to its preferred body part (bladder, rectum, intestines, liver, portal venous system (the veins that carry blood from the intestines to liver, spleen, lungs), depending on its species.  Schistosomiasis is common in many tropical and subtropical areas worldwide. It can be treated safely and effectively with praziquantel. Last updated: 3/15/2013

MalaCards based summary : Schistosomiasis, also known as katayama fever, is related to intestinal schistosomiasis and urinary schistosomiasis. An important gene associated with Schistosomiasis is IL4 (Interleukin 4), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Albendazole and Artemether have been mentioned in the context of this disorder. Affiliated tissues include liver, skin and spleen, and related phenotypes are homeostasis/metabolism and cellular

CDC : 3 Schistosomiasis, also known as bilharzia, is a disease caused by parasitic worms. Although the worms that cause schistosomiasis are not found in the United States, more than 200 million people are infected worldwide. In terms of impact this disease is second only to malaria as the most devastating parasitic disease. Schistosomiasis is considered one of the Neglected Tropical Diseases (NTDs).

Disease Ontology : 12 A parasitic helminthiasis infectious disease that involves infection of the intestine, urinary tract, skin, liver and spleen caused by multiple species of the trematode fluke of the genus Schistosoma. The symptoms include fever, chills, nausea, abdominal pain, diarrhea, malaise, myalgia, liver and spleen enlargement, rash and hematuria.

Wikipedia : 72 Schistosomiasis, also known as snail fever and bilharzia, is a disease caused by parasitic flatworms... more...

Related Diseases for Schistosomiasis

Diseases related to Schistosomiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 491)
# Related Disease Score Top Affiliating Genes
1 intestinal schistosomiasis 34.0 CD40LG IL13 IL4 IL5 STAT6
2 urinary schistosomiasis 33.6 IFNG IL13 IL4 IL5 RNASE3 STAT6
3 neuroschistosomiasis 32.1 CD79A IFNG
4 fascioliasis 30.9 ALB IFNG IL10
5 paragonimiasis 30.5 IL13 IL5 RNASE3
6 strongyloidiasis 30.5 CD79A IFNG IL13 IL5
7 endomyocardial fibrosis 30.5 IL10 IL4 TNF
8 toxocariasis 30.4 CD40LG IGHE RNASE3
9 portal hypertension 30.1 ALB F2 TNF
10 alpha chain disease 30.1 CD40LG CD79A
11 trichuriasis 30.0 IL10 IL13 TNF
12 plasmodium falciparum malaria 30.0 IFNG IL10 TNF
13 appendicitis 30.0 ALB IL10 TNF
14 eosinophilic pneumonia 30.0 IL13 IL5 RNASE3
15 hepatitis b 30.0 ALB F2 IFNG TNF
16 tropical endomyocardial fibrosis 30.0 IL10 IL4 TNF
17 taeniasis 29.9 CD40LG CD79A IL10
18 parasitic helminthiasis infectious disease 29.9 CD40LG CD79A IL10 IL13 IL4 IL5
19 granulomatous hepatitis 29.9 CD40LG CD79A IL4
20 viral hepatitis 29.8 ALB CD40LG F2 TNF
21 hypersplenism 29.8 ALB F2 IFNG
22 salmonellosis 29.7 ALB IFNG IFNGR1
23 alcoholic liver cirrhosis 29.7 ALB F2 TNF
24 onchocerciasis 29.6 IL13 IL2 IL4 IL5 RNASE3
25 mycobacterium tuberculosis 1 29.6 IFNG IFNGR1 IL10 IL4 TNF
26 toxoplasmosis 29.6 CD40LG CD79A IFNG IL10 IL4 TNF
27 diarrhea 29.5 ALB CD40LG CD79A TNF
28 lymphadenitis 29.4 IFNG IFNGR1 IL10 TNF
29 meningitis 29.4 ALB CD40LG IFNG IL10 TNF
30 dermatitis 29.3 IFNG IGHE IL13 IL4 IL5 RNASE3
31 typhoid fever 29.3 ALB IFNG IFNGR1 TNF
32 peritonitis 29.3 ALB F2 IFNG IL10 TNF
33 filariasis 29.3 ALB IFNG IL10 IL2 IL5 TNF
34 echinococcosis 29.3 CD40LG CD79A IFNG IL10 IL5 TNF
35 smallpox 29.3 IFNG IL2 TNF
36 clonorchiasis 29.2 CD79A IFNG IL10 IL2 TNF
37 pneumonia 29.1 CCL3 CD40LG IL10 IL13 IL5 TNF
38 leishmaniasis 29.0 IFNG IFNGR1 IL10 IL13 IL4 IL5
39 paracoccidioidomycosis 28.6 IFNG IL10 IL2 IL4 IL5 TNF
40 chagas disease 28.6 CCL3 IFNG IL10 IL2 TNF
41 human immunodeficiency virus type 1 28.5 CCL3 IFNG IL10 IL2 TNF
42 trypanosomiasis 28.3 ALB CCL3 IFNG IL10 IL2 IL4
43 autoimmune disease 28.1 CD40LG CD79A IFNG IL10 IL2 IL4
44 pulmonary tuberculosis 27.7 CCL3 IFNG IFNGR1 IL10 IL2 IL4
45 asthma 27.7 CCL3 CD40LG CD79A IFNG IGHE IL10
46 acquired immunodeficiency syndrome 27.7 ALB CCL3 CD40LG CD79A IFNG IL10
47 malaria 27.0 ALB CCL3 CD40LG GAPDH IFNG IFNGR1
48 cercarial dermatitis 11.9
49 schistosoma mansoni infection, susceptibility/ 11.9
50 hepatic fibrosis, severe due to schistosoma mansoni infection 10.9

Graphical network of the top 20 diseases related to Schistosomiasis:



Diseases related to Schistosomiasis

Symptoms & Phenotypes for Schistosomiasis

MGI Mouse Phenotypes related to Schistosomiasis:

43 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.33 ALB CD40LG CD79A F2 IFNG IFNGR1
2 cellular MP:0005384 10.3 STAT6 ALB CD40LG CD79A IFNG IFNGR1
3 hematopoietic system MP:0005397 10.29 STAT6 TNF IL4 IL5 LGMN CD40LG
4 immune system MP:0005387 10.25 CD40LG CD79A F2 IFNG IFNGR1 IL10
5 digestive/alimentary MP:0005381 10.21 IL13 IL2 IL4 IL5 TNF ALB
6 endocrine/exocrine gland MP:0005379 10.19 ALB CD40LG IFNG IFNGR1 IL10 IL13
7 liver/biliary system MP:0005370 10.11 ALB CD79A IFNG IFNGR1 IL10 IL2
8 integument MP:0010771 10.06 CD40LG F2 IFNG IFNGR1 IL10 IL13
9 neoplasm MP:0002006 9.97 ALB CD79A IFNG IFNGR1 IL10 IL2
10 reproductive system MP:0005389 9.9 CD40LG F2 IFNG IFNGR1 IL10 IL13
11 renal/urinary system MP:0005367 9.86 ALB CD40LG CD79A IFNG IFNGR1 IL4
12 respiratory system MP:0005388 9.61 IFNG IL10 IL13 IL2 IL4 IL5
13 skeleton MP:0005390 9.28 CD40LG F2 IFNG IFNGR1 IL10 IL13

Drugs & Therapeutics for Schistosomiasis

Drugs for Schistosomiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 134)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Albendazole Approved, Vet_approved Phase 4,Phase 3 54965-21-8 2082
2
Artemether Approved Phase 4 71963-77-4 68911 119380
3
Lumefantrine Approved Phase 4 82186-77-4 6437380
4
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
5
Praziquantel Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 55268-74-1 4891
6 Anthelmintics Phase 4,Phase 3,Phase 2,Phase 1
7 Antifungal Agents Phase 4
8 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
9 Antimalarials Phase 4,Phase 2,Phase 3
10 Antimitotic Agents Phase 4,Phase 3
11 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1
12 Antiprotozoal Agents Phase 4,Phase 2,Phase 3
13 Artemether-lumefantrine combination Phase 4
14 Artemisinine Phase 4,Phase 2,Phase 3
15 Artemisinins Phase 4,Phase 2,Phase 3
16
Zinc Approved, Investigational Phase 3 7440-66-6 32051 23994
17
Artesunate Approved, Investigational Phase 2, Phase 3 88495-63-0 5464098 6917864
18
Pyrimethamine Approved, Investigational, Vet_approved Phase 2, Phase 3 58-14-0 4993
19
Sulfadoxine Approved, Investigational Phase 3,Phase 2 2447-57-6 17134
20
Acarbose Approved, Investigational Phase 3 56180-94-0 441184
21
Bevacizumab Approved, Investigational Phase 3,Phase 2 216974-75-3
22
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
23
Adalimumab Approved Phase 3 331731-18-1 16219006
24
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
25
Tofacitinib Approved, Investigational Phase 3 477600-75-2
26
Iron Approved Phase 3 7439-89-6 23925
27
Tranexamic Acid Approved Phase 3 1197-18-8 5526
28
Myrrh Approved, Nutraceutical Phase 3 9000-45-7
29
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
30
leucovorin Approved, Nutraceutical Phase 2, Phase 3 58-05-9 143 6006
31 Triclabendazole Investigational Phase 3 68786-66-3
32 Micronutrients Phase 3,Not Applicable
33 Trace Elements Phase 3,Not Applicable
34 Vitamins Phase 3,Not Applicable
35 Vaccines Phase 3,Phase 2,Phase 1
36 Folic Acid Antagonists Phase 2, Phase 3
37 Renal Agents Phase 2, Phase 3
38 Sulfalene Phase 2, Phase 3
39 Vitamin B Complex Phase 2, Phase 3
40 Fanasil, pyrimethamine drug combination Phase 3,Phase 2
41
Piperaquine Phase 3 4085-31-8 5079497
42 Cardiac Glycosides Phase 3
43 Glycoside Hydrolase Inhibitors Phase 3
44 Hypoglycemic Agents Phase 3
45 Angiogenesis Inhibitors Phase 3,Phase 2
46 Angiogenesis Modulating Agents Phase 3,Phase 2
47 Anti-Inflammatory Agents Phase 3
48 glucocorticoids Phase 3
49 Hormone Antagonists Phase 3
50 Hormones Phase 3

Interventional clinical trials:

(show top 50) (show all 83)

# Name Status NCT ID Phase Drugs
1 Artemisinin-based Combination Therapy-Intermittent Preventive Treatment (ACT-IPT) Trial Among Schoolchildren in Kassena-Nankana, Ghana Unknown status NCT01459146 Phase 4 Artemether-lumefantrine combination plus albendazole;Artemether-lumefantrine plus Praziquantel plus Albendazole;Albendazole plus Praziquantel
2 Effect of Schistosomiasis Mansoni on HIV Susceptibility and Female Genital Immunology Completed NCT02878564 Phase 4 Praziquantel
3 Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in Brazil Completed NCT00403611 Phase 4 Praziquantel 60 mg/kg;Praziquantel 40 mg/kg
4 A Multinational Trial of the Efficacy of Albendazole Against Soil-transmitted Nematode Infections in Children Completed NCT01087099 Phase 4 Albendazole
5 Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST) Not yet recruiting NCT02868385 Phase 4 4x Praziquantel;1x Praziquantel
6 Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in People With Schistosomiasis Not yet recruiting NCT02734186 Phase 4 Praziquantel
7 A Randomized, Double-Blind, Placebo Controlled Study of NPC-02 in Patients With Zinc Deficiency Unknown status NCT02337569 Phase 3 NPC-02
8 Safety and Efficacy of Mirazid for Schistosomiasis Treatment Completed NCT01529710 Phase 3 Myrrh
9 Efficacy of Bilhvax in Association With Praziquantel for Prevention of Clinical Recurrences of Schistosoma Haematobium Completed NCT00870649 Phase 3
10 Schistosoma Haematobium Infections and Praziquantel Completed NCT01558336 Phase 3 praziquantel
11 Comparing Praziquantel Versus Artesunate + Sulfamethoxypyrazine/Pyrimethamine for Treating Schistosomiasis Completed NCT00510159 Phase 2, Phase 3 Artesunate+Sulfamethoxypyrazine/pyrimethamin;Praziquantel
12 Impact IPT With Sulfadoxine-pyrimethamine or Sulfadoxine-pyrimethamine Plus Piperaquine in Schoolchildren Completed NCT01722539 Phase 3 Sulfadoxine-pyrimethamine;Piperaquine;Albendazole;Praziquantel
13 Acarbose and Secondary Prevention After Coronary Stenting Completed NCT00221156 Phase 3 Acarbose
14 Intravitreal Bevacizumab and Triamcinolone Associated to Laser Photocoagulation for Diabetic Macular Edema(IBeTA) Completed NCT00997191 Phase 3 Intravitreal triamcinolone;Intravitreal bevacizumab
15 A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira®) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02). Completed NCT02480153 Phase 3
16 A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis Completed NCT02281552 Phase 3 Tofacitinib;Tofacitinib
17 Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan Completed NCT00661661 Phase 3 CP-690,550
18 The Chinese-made Praziquantel for Treatment of Schistosoma Haematobium Recruiting NCT03133832 Phase 3 Companion Tablet
19 Haemorrhage Alleviation With Tranexamic Acid- Intestinal System Recruiting NCT01658124 Phase 3 Tranexamic Acid;Placebo
20 A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD) Recruiting NCT03114657 Phase 3 Crenezumab;Placebo
21 IV Ferric Carboxymaltose Compared With Oral Iron in the Treatment of Iron Deficiency Anemia at Delivery in Tanzania Active, not recruiting NCT02541708 Phase 3 Ferric carboxymaltose;Ferrous sulfate + folic acid
22 CREAD Study: A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD) Active, not recruiting NCT02670083 Phase 3 Crenezumab;Placebo
23 A Study to Compare ABT-494 Monotherapy to Methotrexate Monotherapy in Subjects With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate Active, not recruiting NCT02706873 Phase 3 ABT-494 matching placebo;Methotrexate;Methotrexate matching placebo;ABT-494
24 Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD) Not yet recruiting NCT03443973 Phase 3 Gantenerumab;Placebo
25 Activity of Mefloquine Against Urinary Schistosomiasis Completed NCT01132248 Phase 2 Mefloquine;S/P
26 Schistosoma Mansoni Morbidity in Children Aged 1-5 Years Completed NCT01901484 Phase 2 Praziquantel
27 S. Japonicum and Pregnancy Outcomes Completed NCT00486863 Phase 2 Praziquantel
28 Study of Safety and Immune Response of the Sm14 Vaccine in Adults of Endemic Regions Completed NCT03041766 Phase 2 GLA-SE solution
29 Trial to Investigate the Effect of Schistosoma Mansoni Infection on the Response to Vaccination With MVA85A in BCG-vaccinated African Adolescents Completed NCT02178748 Phase 2
30 Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab Completed NCT00864838 Phase 2 Acetazolamide;Brimonidine tartarate
31 An Open Label Dose Finding Safety and Efficacy in Children and Infants Infected With Schistosomiasis (S.Mansoni) Recruiting NCT02806232 Phase 2 Biltricide (racemate praziquantel) oral tablets;Racemate Praziquantel ODT;Levo Praziquantel ODT
32 A Study to Compare Upadacitinib (ABT-494) to Placebo in Subjects With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs Active, not recruiting NCT02720523 Phase 2 Placebo;ABT-494
33 Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis Completed NCT01154049 Phase 1
34 Clinical Trial of Bilhvax,a Vaccine Candidate Against Schistosomiasis Completed NCT01512277 Phase 1
35 A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults Completed NCT02337855 Phase 1
36 Praziquantel-Pharmacokinetic Study Completed NCT01288872 Phase 1 Praziquantel
37 Safety and Immunogenicity Study of a DNA Vaccine Combined With Protein Vaccine Against HIV/AIDS Completed NCT02376582 Phase 1
38 A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults Not yet recruiting NCT03110757 Phase 1
39 Controlled Human Infection for Vaccination Against Streptococcus Pyogenes Not yet recruiting NCT03361163 Phase 1
40 Evaluation of Strategies for Improved Uptake of Preventive Treatment for Intestinal Schistosomiasis Unknown status NCT01869465
41 Antioxidant Supplements in the Reversal of Schistosomal Peri-portal Fibrosis Unknown status NCT01260012
42 A Study of Co-infections of HIV-1 and Schistosoma Mansoni and Its Impact on Praziquantel Treatment Outcomes Unknown status NCT01541631 Praziquantel and Albendazole;Praziquantel and Albendazole;Praziquantel and Albendazole
43 Gene Expression Profile of Breast Cancer Samples After Vitamin D Supplementation Unknown status NCT00926315 Not Applicable calcitriol;Calcitriol
44 Health Benefits of Repeated Treatment in Pediatric Schistosomiasis Completed NCT01424410
45 Arachidonic Acid Treatment Against Schistosomiasis Infection in Children Completed NCT02144389 Praziquantel (PZQ)
46 Women and Children as the Focus for Control of Schistosomiasis Infections in the Irrigations Area of Burkina Faso Completed NCT00463528
47 Assessment of Anaemia Attributable to Schistosomiasis in School Children in Kenya: Mechanisms and Effect of Treatment Completed NCT00414479 praziquantl, iron, ACT
48 Urinary Schistosomiasis Infection Completed NCT00138450
49 Schistosomiasis in Women of Reproductive Age in Burkina Faso: Implications for Control Completed NCT00463632
50 Schistosomiasis in Formal and Non-Formal Schools in Uganda: Implications for Control Programmes Completed NCT00463593

Search NIH Clinical Center for Schistosomiasis

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Genetic Tests for Schistosomiasis

Anatomical Context for Schistosomiasis

MalaCards organs/tissues related to Schistosomiasis:

38
Liver, Skin, Spleen, Testes, Kidney, Lung, Colon

Publications for Schistosomiasis

Articles related to Schistosomiasis:

(show top 50) (show all 1408)
# Title Authors Year
1
Expanding molecular diagnostics of helminthiasis: Piloting use of the GPLN platform for surveillance of soil transmitted helminthiasis and schistosomiasis in Ghana. ( 29370166 )
2018
2
Evaluation of transient elastography in assessing liver fibrosis in patients with advanced schistosomiasis japonica. ( 29355611 )
2018
3
The use of gold nanorods as a new vaccine platform against schistosomiasis. ( 29428201 )
2018
4
Paediatric schistosomiasis: What we know and what we need to know. ( 29420537 )
2018
5
Knowledge, attitudes and practices on Schistosomiasis in sub-Saharan Africa: a systematic review. ( 29347919 )
2018
6
Underestimation of the global burden of schistosomiasis. ( 29413041 )
2018
7
Underestimation of the global burden of schistosomiasis - Authors' reply. ( 29413043 )
2018
8
Historical perspective: Revisiting the St. Lucia Project, a multi-year comparison trial of schistosomiasis control strategies. ( 29385131 )
2018
9
Schistosomiasis and Strongyloidiasis Recommendations for Solid-Organ Transplant Recipients and Donors. ( 29381575 )
2018
10
Eggs and Magnetism: New Approaches for Schistosomiasis Diagnosis. ( 29422443 )
2018
11
Rifaximin Reduces Markers of Inflammation and Bacterial 16S rRNA in Zambian Adults with Hepatosplenic Schistosomiasis: A Randomized Control Trial. ( 29436337 )
2018
12
The Spatial-Temporal Trend Analysis of Schistosomiasis from 1997 to 2010 in Anhui Province, Eastern China. ( 29436347 )
2018
13
Could diet composition modulate pathological outcomes in schistosomiasis mansoni? A systematic review of in vivo preclinical evidence. ( 29400268 )
2018
14
Schistosomiasis in a returning international traveler with cyclic fevers and diarrhea. ( 29449243 )
2018
15
Praziquantel Targets M1 Macrophages and Ameliorates Splenomegaly in Chronic Schistosomiasis. ( 29061758 )
2018
16
Defining the Pathways of Urogenital Schistosomiasis-Associated Urothelial Carcinogenesis through Transgenic and Bladder Wall Egg Injection Models. ( 28889378 )
2018
17
Praziquantel for the treatment of schistosomiasis during human pregnancy. ( 29403101 )
2018
18
18F-NaF PET/CT Finding in a Patient With Abdominal Discomfort After Schistosomiasis. ( 29356743 )
2018
19
Comparison of three data mining models for prediction of advanced schistosomiasis prognosis in the Hubei province. ( 29447165 )
2018
20
Drug Repurposing for Schistosomiasis: Combinations of Drugs or Biomolecules. ( 29401734 )
2018
21
Cellular immunodeficiency related to chronic dermatophytosis in a patient with Schistosoma mansoni infection: can schistosomiasis induce immunodeficiency? ( 28327819 )
2017
22
The role of ST2 and ST2 genetic variants in schistosomiasis. ( 28189770 )
2017
23
New index for the diagnosis of liver fibrosis in Schistosomiasis mansoni. ( 28079240 )
2017
24
A comparative study on the efficacy of praziquantel and albendazole in the treatment of urinary schistosomiasis in Adim, Cross River State, Nigeria. ( 28911129 )
2017
25
Cerebral schistosomiasis: diffusion-weighted imaging helps to differentiate from brain glioma and metastasis. ( 28090792 )
2017
26
Knowledge, attitude, and practices on intestinal schistosomiasis among primary schoolchildren in the Lake Victoria basin, Rorya District, north-western Tanzania. ( 28934944 )
2017
27
Prevalence of Urinary Schistosomiasis in Migrants in Apulia, a Region of Southern Italy, in the Years 2006-2016. ( 29435460 )
2017
28
Assessment of schistosomiasis and soil-transmitted helminths prevalence in school-aged children and opportunities for integration of control in local health services in Kwilu Province, the Democratic Republic of the Congo. ( 28853206 )
2017
29
Epidemiology of Urinary Schistosomiasis among School Children in the Alsaial Alsagair Village, River Nile State, Sudan. ( 28761490 )
2017
30
Effects of schistosomiasis on susceptibility to HIV-1 infection and HIV-1 viral load at HIV-1 seroconversion: A nested case-control study. ( 28945756 )
2017
31
Diagnosis of coinfection by schistosomiasis and viral hepatitis B or C using 1H NMR-based metabonomics. ( 28763497 )
2017
32
Urinary schistosomiasis in school aged children of two rural endemic communities in Edo State, Nigeria. ( 28970097 )
2017
33
Using the hierarchical ordinal regression model to analyse the intensity of urinary schistosomiasis infection in school children in Lusaka Province, Zambia. ( 28219411 )
2017
34
Urinary schistosomiasis:<i>Schistosoma haematobium</i>infection diagnosed by histopathology. ( 29323093 )
2017
35
The Problem with Diagnosis of Intestinal Schistosomiasis. ( 29033139 )
2017
36
Intestinal schistosomiasis in Uganda at high altitude (>1400A m): malacological and epidemiological surveys on Mount Elgon and in Fort Portal crater lakes reveal extra preventive chemotherapy needs. ( 28162096 )
2017
37
Exploring possibilities for an alternative approach in experimental schistosomiasis mansoni: the peritoneal cavity of mice. ( 28030359 )
2017
38
Recent advances in proteomic applications for schistosomiasis research: potential clinical impact. ( 27937063 )
2017
39
A new global strategy for the elimination of schistosomiasis. ( 27939558 )
2017
40
Corrigendum: Whole genome analysis of a schistosomiasis-transmitting freshwater snail. ( 28832025 )
2017
41
Towards interruption of schistosomiasis transmission in sub-Saharan Africa: developing an appropriate environmental surveillance framework to guide and to support 'end game' interventions. ( 28088239 )
2017
42
Epidemiological, clinical, diagnostic and economic features of an immigrant population of chronic schistosomiasis sufferers with long-term residence in a non-endemic country (North Metropolitan area of Barcelona, 2002-2016). ( 28953954 )
2017
43
Cystic Presentation of Hepatic Schistosomiasis. ( 28924731 )
2017
44
Host regulation of liver fibroproliferative pathology during experimental schistosomiasis via interleukin-4 receptor alpha. ( 28827803 )
2017
45
Impact of old Schistosomiasis infection on the use of transient elastography (Fibroscan) for staging of fibrosis in chronic HCV patients. ( 28851531 )
2017
46
Colorectal cancer in a patient with intestinal schistosomiasis: a case report from Kilimanjaro Christian Medical Center Northern Zone Tanzania. ( 28768520 )
2017
47
Nationwide cross-sectional survey of schistosomiasis and soil-transmitted helminthiasis in Sudan: study protocol. ( 28899362 )
2017
48
Paediatric and maternal schistosomiasis: shifting the paradigms. ( 28910994 )
2017
49
Rapid Risk Assessment Report for Schistosomiasis Epidemic in Jianli County Caused by the Sunk "Oriental Star" Cruise Ship. ( 28914224 )
2017
50
Acute appendicitis due to schistosomiasis: four cases at the Yalgado OuAcdraogo University Hospital of Ouagadougou. ( 28947413 )
2017

Variations for Schistosomiasis

Expression for Schistosomiasis

Search GEO for disease gene expression data for Schistosomiasis.

Pathways for Schistosomiasis

Pathways related to Schistosomiasis according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.1 CCL3 CD40LG CD79A IFNG IFNGR1 IGHE
2
Show member pathways
13.74 CCL3 CD40LG F2 IFNG IFNGR1 IL10
3
Show member pathways
13.63 CCL3 F2 IFNG IFNGR1 IL10 IL13
4
Show member pathways
13.49 CCL3 CD40LG IL10 IL13 IL2 IL4
5
Show member pathways
13.43 CCL3 CD40LG IFNG IFNGR1 IGHE IL10
6
Show member pathways
13.36 CCL3 CD40LG IL10 IL13 IL2 IL4
7
Show member pathways
13.26 CD79A IFNG IFNGR1 IL2 IL4 STAT6
8 12.94 IFNG IFNGR1 IL13 IL2 IL4 IL5
9
Show member pathways
12.86 IFNG IFNGR1 IL13 IL2 IL4 TNF
10
Show member pathways
12.84 CD40LG IFNG IL10 IL13 IL2 IL4
11
Show member pathways
12.72 CD40LG CD79A IFNG IFNGR1 IGHE IL10
12
Show member pathways
12.69 F2 IFNG IL10 IL2 STAT6 TNF
13
Show member pathways
12.69 CD79A IGHE IL13 IL4 IL5 TNF
14 12.69 CD40LG CD79A IFNG IL10 IL2 IL4
15
Show member pathways
12.64 CCL3 IFNG IFNGR1 IL10 IL2 TNF
16
Show member pathways
12.62 IFNG IFNGR1 IL10 IL13 IL2 IL4
17
Show member pathways
12.58 IFNG IFNGR1 IL2 IL4 TNF
18
Show member pathways
12.55 CD40LG IFNG IL10 IL2 IL4 IL5
19
Show member pathways
12.45 ALB F2 IFNG IL2 IL4 TNF
20
Show member pathways
12.42 IFNG IL13 IL4 IL5 TNF
21
Show member pathways
12.38 CD40LG IFNG IFNGR1 IL10 IL4 TNF
22
Show member pathways
12.3 IFNG IFNGR1 IL10 IL13 IL2 IL4
23 12.27 IFNG IFNGR1 IL10 TNF
24
Show member pathways
12.26 IFNG IFNGR1 STAT6 TNF
25
Show member pathways
12.23 IFNG IFNGR1 IL4 TNF
26
Show member pathways
12.23 IFNG IL10 IL13 IL2 IL4 IL5
27 12.22 GAPDH IL10 IL13 TNF
28 12.12 IGHE IL10 IL13 IL4 STAT6 TNF
29
Show member pathways
12.1 CCL3 IFNG IL2 IL4 STAT6
30 12.08 IFNG IL2 IL4 TNF
31 12.07 CD79A IFNG IL10 IL2 IL4 IL5
32
Show member pathways
12.06 IFNG IFNGR1 IL10 IL2 TNF
33 11.96 IFNG IFNGR1 IL10 IL2 STAT6
34 11.93 IFNG IL13 IL2 IL4 IL5
35
Show member pathways
11.88 CD40LG IFNG IL2 IL4 IL5 TNF
36 11.85 IFNG IL10 IL2 TNF
37 11.83 CD40LG IL10 IL4 IL5 TNF
38 11.8 CCL3 IL13 IL4 IL5 TNF
39
Show member pathways
11.78 CD40LG IFNG IL2 TNF
40 11.77 CD40LG IGHE IL10 IL4 IL5 STAT6
41
Show member pathways
11.68 IFNG IL2 TNF
42 11.68 CCL3 IL10 IL13 IL4 TNF
43 11.65 CD40LG IFNG IL10 TNF
44 11.6 IFNG IL2 TNF
45
Show member pathways
11.59 IFNG IFNGR1 TNF
46 11.56 IFNG IL2 TNF
47
Show member pathways
11.52 CCL3 IFNG IL10 IL2 TNF
48 11.47 CD40LG IFNG IL2 IL4 IL5
49 11.46 CCL3 IFNG IL10 IL13 IL2 IL4
50 11.45 IFNG IL13 IL4 IL5 TNF

GO Terms for Schistosomiasis

Cellular components related to Schistosomiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 ALB CCL3 CD40LG F2 IFNG IGHE
2 external side of plasma membrane GO:0009897 9.63 CD40LG CD79A F2 IGHE IL13 TNF
3 blood microparticle GO:0072562 9.56 ALB F2 IGHE SERPINF2
4 extracellular space GO:0005615 9.44 ALB CCL3 CD40LG F2 IFNG IL10

Biological processes related to Schistosomiasis according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 defense response to bacterium GO:0042742 9.93 IGHE IL10 RNASE3 TNF
2 positive regulation of protein phosphorylation GO:0001934 9.86 F2 IFNG IL2 TNF
3 inflammatory response GO:0006954 9.8 CCL3 CD40LG IL10 IL13 IL5 TNF
4 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.79 IFNG IL13 IL2
5 positive regulation of T cell proliferation GO:0042102 9.78 CD40LG IL2 IL4
6 positive regulation of smooth muscle cell proliferation GO:0048661 9.77 IL13 SERPINF2 TNF
7 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 9.74 F2 GAPDH RNASE3
8 positive regulation of podosome assembly GO:0071803 9.65 IL5 TNF
9 immune response GO:0006955 9.65 CCL3 CD40LG IFNG IGHE IL10 IL13
10 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.64 IL10 TNF
11 positive regulation of immunoglobulin secretion GO:0051024 9.64 IL2 IL5
12 negative regulation of fibrinolysis GO:0051918 9.63 F2 SERPINF2
13 B cell proliferation GO:0042100 9.63 CD40LG CD79A IL10
14 positive regulation of isotype switching to IgG isotypes GO:0048304 9.62 IL2 IL4
15 endothelial cell apoptotic process GO:0072577 9.61 IL10 TNF
16 negative regulation of endothelial cell apoptotic process GO:2000352 9.61 IL10 IL13 IL4
17 positive regulation of MHC class II biosynthetic process GO:0045348 9.59 IL10 IL4
18 negative regulation of cytokine secretion involved in immune response GO:0002740 9.58 IL10 TNF
19 type 2 immune response GO:0042092 9.58 IL10 IL4
20 positive regulation of cytokine secretion GO:0050715 9.58 GAPDH IL10 TNF
21 B cell differentiation GO:0030183 9.56 CD40LG CD79A IL10 IL4
22 regulation of immunoglobulin secretion GO:0051023 9.55 CD40LG TNF
23 regulation of isotype switching GO:0045191 9.54 IL10 IL4
24 receptor biosynthetic process GO:0032800 9.52 IL10 TNF
25 positive regulation of isotype switching to IgE isotypes GO:0048295 9.51 IL4 STAT6
26 negative regulation of complement-dependent cytotoxicity GO:1903660 9.49 IL13 IL4
27 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.48 IFNG TNF
28 positive regulation of B cell proliferation GO:0030890 9.46 IL13 IL2 IL4 IL5
29 positive regulation of vitamin D biosynthetic process GO:0060557 9.37 IFNG TNF
30 regulation of receptor activity GO:0010469 9.32 CCL3 CD40LG F2 IFNG IL10 IL13

Molecular functions related to Schistosomiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.35 F2 IL10 IL2 IL4 IL5
2 cytokine activity GO:0005125 9.28 CCL3 CD40LG IFNG IL10 IL13 IL2

Sources for Schistosomiasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....